Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| KALVISTA PHARMACEUTICALS | 14 | 1 | +39,01 % | ||
| BIOGEN | 12 | 54 | +5,84 % | ||
| REGENERON PHARMACEUTICALS | 11 | 22 | -5,45 % | ||
| BRIDGEBIO PHARMA | 11 | - | +1,71 % | ||
| INCYTE | 8 | 25 | +2,99 % | ||
| KINIKSA PHARMACEUTICALS | 7 | 11 | +0,26 % | ||
| AMGEN | 6 | 27 | -0,14 % | ||
| WAVE LIFE SCIENCES | 6 | 2 | -3,88 % | ||
| ORUKA THERAPEUTICS | 5 | - | -7,09 % | ||
| BIONTECH | 4 | 13 | -0,98 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18:10 | Regeneron's quarterly sales of Eylea drop below $1B for the first time in 8 years | 2 | FiercePharma | ||
| 18:10 | Sanofi: Annual General Meeting of April 29, 2026 - Belén Garijo appointed as Director and Chief Executive Officer of Sanofi | 168 | GlobeNewswire (Europe) | Annual General Meeting of April 29, 2026
Belén Garijo appointed as Director and Chief Executive Officer of Sanofi
Paris, April 29, 2026. Sanofi's Mixed General Meeting of Shareholders convened... ► Artikel lesen | |
| 18:10 | Is Amneal (AMRX) a Solid Growth Stock? 3 Reasons to Think "Yes" | 2 | Zacks | ||
| 18:10 | Italienische Pharmafirma Chiesi schluckt US-Rivalen KalVista | 3 | Reuters Deutschland | ||
| 17:58 | Chiesi signs $1.9bn deal to buy KalVista and its HAE drug | 2 | pharmaphorum | ||
| 17:46 | Chiesi to buy KalVista in $1.9B deal for rare disease drug | 1 | BioPharma Dive | ||
| 17:42 | Chiesi Group To Acquire KalVista Pharmaceuticals For $1.9 Billion To Expand Rare Disease Portfolio | 1 | pulse2.com | ||
| 17:42 | Morningstar Rebrands CRSP Market Indexes, Cementing Position As Top-Tier Index Provider | 1 | pulse2.com | ||
| 17:34 | Regeneron im ersten Quartal 2026: Dupixent treibt Umsatz um 19 % an | 7 | Investing.com Deutsch | ||
| 17:30 | Summers Value Fund adds TBPH, exits ADMA among Q1 moves | 3 | Seeking Alpha | ||
| 17:18 | Regeneron Q1 2026 slides: Dupixent drives 19% revenue growth | 4 | Investing.com | ||
| 17:06 | Ionis Q1 2026 slides: commercial revenue surges, guidance raised | 2 | Investing.com | ||
| 17:06 | Amgen Q1 Preview: What to expect | 12 | Seeking Alpha | ||
| 16:34 | Biogen Q1 2026: Gewinn übertrifft Prognosen, Apellis-Übernahme soll Wachstum beschleunigen | 13 | Investing.com Deutsch | ||
| 16:30 | Biontech vor kritischer Marke: Warum Sie jetzt genau hinschauen sollten - Die Fakten auf einen Blick | Hebelschein-Spekulant | |||
| 16:26 | Ultragenyx Pharmaceutical (RARE) Garnering Bullish Sentiment With Forthcoming GTX-102 Phase 3 Angelman Trial | 2 | Insider Monkey | ||
| 16:26 | Ocular Therapeutix Inc. (OCUL) Appears Highly Attractive Following SOL-1 Clinical Trial Data | 4 | Insider Monkey | ||
| 16:26 | What Makes Denali Therapeutics (DNLI) One of the Best Biotech Stocks to Invest in | 2 | Insider Monkey | ||
| 16:26 | Crinetics Pharmaceuticals (CRNX) is One of the Best Biotech Stocks to Buy, Here is Why | 1 | Insider Monkey | ||
| 16:26 | Beam Therapeutics (BEAM) Reveals Encouraging Results From Risto-Cel Phase 1/2 BEACON Study | 2 | Insider Monkey |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.